myAACR
Donate Today
Skip to Content

Progress Against Cancer

Home Patients, Caregivers, and Advocates Progress Against Cancer Research Page 12

Recent Progress: Cancer Discoveries

AACR Grantee Identifies Novel Combination Therapy for Epithelial Ovarian Cancer

AACR Grantee Identifies Novel Combination Therapy for Epithelial Ovarian Cancer

Epithelial ovarian cancer is by far the most common ovarian cancer subtype, accounting for 90 percent of ovarian cancers. The complex genetic heterogeneity of this disease makes treatment particularly difficult. While the introduction of PARP inhibitors to treat ovarian cancers has been a major advancement, only the approximately 50 percent of epithelial ovarian cancers that exhibit defective DNA repair via homologous recombination are potentially responsive to PARP inhibition. Moreover, the development of therapeutic resistance remains a challenge.